Horizon Health International Corp. Appoints Chairman of the Board
September 14 2010 - 9:40AM
Marketwired
HORIZON HEALTH INTERNATIONAL CORP. (PINK SHEETS: HZHI) (Horizon)
appoints Dr. Max Arella as Chairman to its Board of Directors.
Mr. Di Fruscia, President of Horizon is delighted to announce
that Dr. Max Arella has accepted the appointment as Chairman of the
Board of Horizon.
Dr. Arella received his M. Sc. in Microbiology from University
of Montreal, Canada and his Ph.D. in Virology from Institute
Armand-Frappier-University of Quebec, Canada.
Dr. Arella's career started in France in 1979 as a lecturer
during 3 years at the University of Rouen, follow by a
post-doctoral fellowship at the prestigious Roche Institute of
Molecula Biology in Nutley, New Jersey. In 1984 he accepted a
position as a Virology professor at the Institute
Armand-Frappier-University of Quebec that was later renamed
INRS-Institute Armand-Frappier. Dr. Arella held the position of
acting chairman of the Virology Research Center between 1993 and
1998. He collaborated for many years with the private sector in
technology-transfert positions and management of intellectual
property. He has supervised many master-doctoral and post-doctoral
students, published and communicated in molecular biology and
virology and collaborated with small, medium and large size
pharmaceutical companies developing new pharmaceuticals, medical
devices and natural products. Over the years Dr. Arella acquired an
impressive network of contacts in the academic, industrial and
financial community and he is actively involved in projects in
private and public companies. Dr. Arella retired in November
2009.
President Di Fruscia stated: "Dr. Arella brings knowledge,
contacts and leadership, invaluable to the future long term growth
and inevitable success of Horizon. We are delighted to have Dr.
Arella as the Chairman of our organization".
The Company's business:
HORIZON's Subsidiary 'New Release Lactoferrin Pharma Canada
Inc.' is an emerging specialty nutraceutical company that is
committed to supply its enteric lactoferrin, and new formulations
of Lactoferrin and nutraceuticals. We are introducing enteric
lactoferrin products in the market as a supplemental food and have
also undertaken projects to further study nutraceutical products
and increase their market-shares and applications. The company's
proprietary enteric lactoferrin, obtained from a licensing
agreement from Japan, has proved his efficacy and potential
compared to all lactoferrin-containing products.
Forward-looking statements in this release are made pursuant to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements involve risks
and uncertainties, including, without limitation, continued
acceptance of the Company's products, increased levels of
competition, new products and technological changes, dependence
upon third-party suppliers, intellectual property rights, and other
risks detailed from time to time in the Company's periodic
reports.
Contacts: Horizon Health International Corp. Rocco Di Fruscia
President and CEO 514 586 3799 horizonhealth@shaw.ca
www.horizonhealthinternational.com
Horizon Health (CE) (USOTC:HZHI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Horizon Health (CE) (USOTC:HZHI)
Historical Stock Chart
From Apr 2023 to Apr 2024
